# Theoria Science Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/theoria-science-co

- Industry: Healthcare Specialists
- Headquarters: Tokyo, Japan
- Website: www.theoria.co.jp
- Total disclosed funding: $3.3M
- Latest round: Series A (Aug 2, 2021)
- Investors on record: 3

## About

Theoria Science Co., Ltd. focuses on pioneering diagnostic and therapeutic innovations for cancer, harnessing advanced exosome research to enhance cancer detection and treatment methods in the healthcare sector.Founded in 2012 and headquartered in Tokyo, Japan, Theoria Science Co., Ltd. specializes in cancer diagnostics and therapeutics. The company has engaged in 2 deals, with their most recent deal occurring on August 2, 2021, during their Series A funding round. In this round, they raised JPY 350.000 mn from SBI Investment, which contributed to their total amount raised of JPY 350.000 mn, supporting a current company valuation of JPY 1,827.725 mn.Theoria Science Co., Ltd. specializes in the development of diagnostic and therapeutic methods for cancer through advanced exosome research. Their core offerings include cancer screening tests, such as those aimed at the early detection of pancreatic cancer. By leveraging their expertise in nucleic acid medicines, bioimaging, stem cells, regenerative medicine, cellular engineering, and molecular oncology, the company seeks to address the complexities of cancer treatment and diagnosis. The products are primarily targeted towards healthcare providers, research institutions, and pharmaceutical companies involved in oncology, operating across international markets including Japan, North America, and Europe. The company's commitment to innovation is evident in their ongoing research initiatives, which expand the potential applications of exosomes beyond oncology, aiming to impact a wide range of diseases.Theoria Science generates revenue through partnerships with healthcare organizations and research institutions that utilize their diagnostic and therapeutic solutions. These transactions occur on a B2B basis, where clients engage with the company for the development and provision of specialized testing and treatment services. Their flagship products, including specific cancer screening tests, are marketed through direct sales channels to healthcare providers, ensuring integration into clinical practices. The company's revenue structure is supported by subscription models for ongoing services, as well as one-time fees for product implementation and usage. While specific pricing details for their offerings remain undisclosed, the company is focused on enhancing patient care and improving health outcomes through its innovations in exosome research.In August 2021, Theoria Science raised JPY 350.000 mn in Series A funding to bolster its R&D system and accelerate its drug discovery business. The company plans to develop and launch new products aimed at further improving cancer diagnostics and therapeutics. Additionally, they are looking to expand their market presence into North America and Europe, targeting completion of these efforts by 2023. The funding will be utilized to enhance their research capabilities and support the launch of their upcoming innovations in cancer care.

## Funding rounds

- Series A, Aug 2, 2021 — SMBC Venture Capital, Taisho Pharmaceutical Co., Ltd.
- Series A, Jun 5, 2020, $3.3M — SBI Investment

## Investors

- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series A
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A
- Taisho Pharmaceutical Co., Ltd. — Series A